Literature DB >> 2776368

High incidence of chromosomal lesions involving C-heterochromatin in four human melanoma lines.

L Larizza1, L Doneda, M Rodolfo, G Fossati.   

Abstract

Cytogenetic analysis of early in vitro cultures derived from human melanomas, two primary tumors (Me 10538, Me 1402) and two metastatic lesions in the same patient (Me 665/1, Me 665/2) showed non-random involvement of C-heterochromatin in clonal chromosome rearrangements. Marker chromosomes with C- and DA-Dapi-positive bands were identified in one of the metastases, Me 665/1 (m1) and in the two primary tumors, Me 10538 (m2) and Me 1402 (m3). C-positive fragments predominated in the other metastasis, Me 665/2, which lacked C-regions intercalated in rearranged chromosomes, and were also detected with appreciable frequency in the Me 665/1 and Me 1402 cells. The frequencies of marker chromosomes and their mean number per cell allowed m2 and m1 to be considered as early markers of tumor formation and m3 as a marker of tumor progression. Dissection of chromosome structure, including the origin of the intercalated C-band, has so far been achieved only with the m2 chromosome of the primary tumor Me10538. This was the only cell line which displayed few C-fragments and a narrow chromosomal distribution with a well defined mode. A gradient of malignancy could be detected in the four cell lines, by local and disseminated tumor growth in xenotransplanted mice, with the two primary melanomas 10538 and the 1402 cells at the lowest and upper extremes. This gradient closely parallels the increase in cytogenetic heterogeneity and C-heterochromatin lesions from the 10538 to the 1402 cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776368     DOI: 10.1007/BF01753674

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  23 in total

Review 1.  The role of heterochromatin in the origin of isochromosome 1 in neoplastic cells.

Authors:  R S Verma; M J Macera; A Babu
Journal:  Eur J Cancer Clin Oncol       Date:  1988-05

2.  Marker chromosome 1q+ in acute lymphocytic leukemia.

Authors:  I Petković; M Nakić; A Tiefenbach; J Konja; M Kastelan; L Rajić; R Feminić-Kes
Journal:  Cancer Genet Cytogenet       Date:  1987-02

Review 3.  Karyotypic progression in human tumors.

Authors:  S R Wolman
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

4.  Analysis of double minutes and double minute-like chromatin in human and murine tumor cells using antikinetochore antibodies.

Authors:  T Haaf; M Schmid
Journal:  Cancer Genet Cytogenet       Date:  1988-01

5.  Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice.

Authors:  R Giavazzi; D E Campbell; J M Jessup; K Cleary; I J Fidler
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

6.  Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes.

Authors:  G Fossati; A Balsari; D Taramelli; M L Sensi; G Pellegris; M Nava; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  Cytogenetic findings in a malignant melanoma and its derived cell line.

Authors:  J H Ohyashiki; K Ohyashiki; Z Gibas; C Karakousis; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1986-09

8.  Multiple telomeric associations of a trisomic whole q arm of chromosome 1 in a child with acute lymphoblastic leukemia.

Authors:  S C Raimondi; S T Ragsdale; F Behm; G Rivera; D L Williams
Journal:  Cancer Genet Cytogenet       Date:  1987-01

9.  Break points in chromosome #1 abnormalities of 218 human neoplasms.

Authors:  V Brito-Babapulle; N B Atkin
Journal:  Cancer Genet Cytogenet       Date:  1981-11

10.  Tumorigenicity and dissemination of primary and metastatic human melanomas implanted into different sites in athymic nude mice.

Authors:  M Rodolfo; A Balsari; C Clemente; G Parmiani; G Fossati
Journal:  Invasion Metastasis       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.